Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

A Couple Of News Dumps You May Have Missed On Tuesday Night

GPRO, ARWR

The entire nation was glued to their TV sets or smartphones for the latest U.S. election updates. This also proved to be a convenient time for companies to release a "news dump" - a potentially negative news release on a much bigger news day.

Intentional or not, the following reports and announcements were released Tuesday evening, which coincided with the presidential election coverage.

GoPro Recalls Drones

GoPro Inc (NASDAQ: GPRO) announced that a safety issue involving its new drone product has prompted a full recall.

GoPro sold approximately 2,500 units of its drone, called Karma, but consumers are now urged to return the drone to their point of purchase after the company discovered that a "very small number of cases" of drones lost power while flying in the air.

Arrowhead Pharmaceuticals Issues FDA Update

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) announced an update to an ongoing clinical trial called Heparc-2004, which is evaluating its ARC-520 drug for the treatment of chronic hepatitis B virus infections.

Arrowhead said it was notified by the U.S. Food & Drug Administration that the agency is requesting the company put its clinical trial on hold.

Arrowhead was also requested to submit responses to the FDA's questions and concerns. The company did note that the clinical hold was not based on any human findings.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today